Teprotumumab
Information
- Drug Name
- Teprotumumab
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| colorectal cancer | KRAS MUTATION KRAS MUTATION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 21985784 | Detail |
| Ewing sarcoma of bone |
PTPRD p.Val253Ile (p.V253I) ( ENST00000355233.9, ENST00000356435.9, ENST00000381196.9, ENST00000397606.7, ENST00000397611.7, ENST00000397617.8, ENST00000486161.5, ENST00000537002.5, ENST00000540109.5 ) PTPRD p.Val253Ile (p.V253I) ( ENST00000355233.9, ENST00000356435.9, ENST00000381196.9, ENST00000397606.7, ENST00000397611.7, ENST00000397617.8, ENST00000486161.5, ENST00000537002.5, ENST00000540109.5 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 4 | 23800680 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Preclinial data from KRAS mutant colorectal cancer... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Report of complete response to IGF1-R antibody, wi... | PTPRD |
PTPRD p.Val253Ile (p.V253I) ( ENST00000355233.9, ENST00000356435.9, ENST00000381196.9, ENST00000397606.7, ENST00000397611.7, ENST00000397617.8, ENST00000486161.5, ENST00000537002.5, ENST00000540109.5 ) PTPRD p.Val253Ile (p.V253I) ( ENST00000355233.9, ENST00000356435.9, ENST00000381196.9, ENST00000397606.7, ENST00000397611.7, ENST00000397617.8, ENST00000486161.5, ENST00000537002.5, ENST00000540109.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05002998 | Active, not recruiting | Phase 4 | TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study | September 16, 2021 | October 2025 |
| NCT04040894 | Approved for marketing | Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease | |||
| NCT03298867 | Completed | Phase 3 | Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study | October 4, 2017 | November 30, 2020 |
| NCT03461211 | Completed | Phase 3 | Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study | April 16, 2018 | February 17, 2021 |
| NCT06389578 | Completed | Phase 1 | A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease | July 14, 2022 | September 12, 2023 |
| NCT02103283 | Completed | Phase 1 | A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME) | October 2014 | August 2016 |
| NCT01868997 | Completed | Phase 2 | Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease | July 2013 | February 22, 2017 |
| NCT06248619 | Recruiting | Phase 3 | A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease | June 21, 2024 | March 1, 2026 |